Corporate Presentation
Rare diseases
SBS
Glepaglutide has best-in-class potential as a next-
generation GLP-2 therapy for patients with SBS
.
Gattex® (teduglutide):
only currently available GLP-2 treatment
Effective half-life of 1.3 hours at steady state
• 0.05 mg/kg daily subcutaneous dosing via vial and syringe
• Multi-step reconstitution process
Glepaglutide:
ZEAL&
a long-acting stable GLP-2 analog*
Forms depot at the injection site
ZEALAND PHARMA
Effective half-life of ~88 hours at steady state1
Expected 10 mg twice-weekly subcutaneous dosing
• Ready-to-use auto-injector with needle protection
• Regulatory decision (PDUFA) with US FDA in Dec-2024
Vial of GATTEX
Alcohol
swab pads
Diluent syringe
(white cap)
Needle for
reconstitution
Figure A
Plastic dosing syringe
Source: https://www.gattex.com/resources-and-support/
Ande) nyection
me
10 mg/0.5 m
* Investigational product, not approved for distribution; IP exclusivity: Compound patent 2026
+ 5 years PTE; Dosing regime (pending) 2038, Clinical formulation (pending) 2039
1 Agersnap M. et al, 2022, Clin Drug Investigation; 42(12):1093-1100
39View entire presentation